Cidara Therapeutics’ Post

#Sigma and #ChemistWarehouse's proposed merger raises competition concerns The ACCC has outlined preliminary competition concerns with Sigma Healthcare Limited’s (ASX: SIG) proposed acquisition of Chemist Warehouse Group Holdings in a Statement of Issues published today. “This is a major structural change for the pharmacy sector, involving the largest pharmacy chain by revenue merging with a key wholesaler to thousands of independent pharmacies that in turn compete against Chemist Warehouse,” ACCC Commissioner Stephen Ridgeway said. “We have identified a range of preliminary competition concerns, including at the retail level and as a result of the proposed integration of the merged firm across the wholesale and retail level. We want to hear from interested parties, including rival pharmacies as we continue this review.”.... https://bit.ly/3Rt9u7D #Australia #Business #Pharmacy Via accc.gov.au

News of possible transaction in health Morgen Stanley is planning to sell its 17% stake in Sahajanand Medical Technologies (SMT). Tentative valuation Rs. 3500-4000 cr (3.5-4x of FY 24 expected revenue) PE acquired this stake for RS. 160 cr in FY 18 - indicates 3.5x-4x return in five years SMT is a known name in the domestic stent market. The volume of drugs eluting stents holds 31% market share. after the price cap by NPPA, local manufacturers acquired a larger market share. #healthcareindustry #acquisitions #privateequityfunds #healthcarefinance https://lnkd.in/dTu9y9CM

📍 Mergers and acquisitions have the ability to save numerous industries, including medical devices, industrials, retailers, aerospace, utilities, foods and pharmaceuticals, and many more. Right now, however, the FTC has been very aggressive in trying to stymie any deal that comes their way, sometimes merely to hold them up until a judge lets them through, and sometimes successfully just shooting them down. #TrustedAdvisors #DealTeam #TeamEminae #BusinessSale #PeopleAndProcesses #MergersAndAcquisitions #M&A #BusinessSellingTips #EminaeNetwork #BusinessInsights #BusinessValuation #SellingABusiness

In a dynamic shift within the #pharmaceuticalindustry, Sigma Healthcare Ltd faces a 6% #shares drop amidst the Chemist Warehouse merger complexities. The ACCC's preliminary concerns cause a stir among investors and bring forth debate over the future of the Australian pharmacy sector. Key aspects to look out for: 🔹 Potential #market restructure raising entry barriers 🔹 Higher consumer prices due to decreased competition 🔹 ACCC's review and the decision, crucial for the merger outcome Industry professionals, #investors, and analysts are keeping a close watch on how Sigma's share price and this proposed merger will influence the #retailpharmacy landscape. What are your thoughts on the implications of this merger? Read in detail about the unfolding events here: https://lnkd.in/dYDV-62j

We wanted to take this opportunity to reflect on 2023 and what an amazing year it has been in the chemicals and life sciences industry.   CCD Partners’ Year in Review:  • 552 deals tracked in chemicals and life sciences M&A • 280 of these deals were acquisitions and divestments • 2,700 new businesses and investors contacted We want to thank all those involved in making these milestones a reality and are looking forward to all the opportunities that 2024 will bring.    #ChemicalIndustry #Pharma #MergersandAcquisitions #HappyNewYear

What higher reverse #breakup fees mean for #healthcare sector #antitrust risk? - Target companies are seeking more and higher reverse breakup fees in case their takeover is hampered by US antitrust enforcement - This uptick in financial safeguards for a possible failed deal reflects the more aggressive stance by the #ftc and #doj under the #bidenadministration - 2/3 #deals announced under #biden Administration’s #ftc have buyer #termination fee - Average amount nearly x2 to 4.76% of deal value from 2.83% The majority of healthcare-sector deals are now reviewed by the FTC, and 58% of #mergers announced since #LinaKhan was sworn in as chair (06/21) included a reverse breakup fee, compared to 25% of deals that were announced in the c.900 days before that. This analysis is based on deals involving US-listed companies – mainly in #pharma and #biotech (announced since Jan 2019 with a deal value of USD 3bn + and a total value of USD 11.5trn incl the largest Bristol Myers Squibb acquisition of Celgene (USD 87.7bn). In 7 out of 28 mergers announced between Jan. 2019 and 15/06/21, a reverse breakup fee was agreed between the parties. 21 out of 36 deals announced between 16/06/21 and 13/12/23 had a buyer termination fee, often with specific reference to regulatory approvals.  The average share of the fee compared to purchase price nearly doubled from 2.83% before the current administration’s FTC, to 4.76% since then. An even stronger effect can be seen since the FTC’s unprecedented challenge of Amgen USD 28bn acquisition of  Horizon in May this year: 86% of deals include a reverse termination fee, with a 5.38% price tag. One deal most clearly exemplifies the stark difference in a pre-and-post-Biden Administration regulatory review: UnitedHealth Group #takeover of  Change Healthcare. That deal was announced back in Jan. 2021 and with no reverse break-up fee. The DoJ challenged the deal in Feb 2022, three months after Assistant Attorney General #JonathanKanter was confirmed, and, as a result, the companies extended their merger agreement through the end of the year and added a reverse termination fee of USD 650m, working out to 4.8% of deal value. AbbVie recent announcements of acquisitions of ImmunoGen, Inc. and Cerevel Therapeutics show how high the possible penalty can be for a buyer if a deal falls through. In the ImmunoGen, Inc. deal, the reverse breakup fee is 6.84% of the USD 9.6bn purchase price. In the Cerevel Therapeutics deal, AbbVie promised to pay 7.51% of the USD 8.7bn value if it does not consummate for regulatory reasons. The FTC this week challenged Sanofi acquisition of an exclusive licence for Maze Therapeutics’ therapy in development for treatment of Pompe disease. The companies have abandoned the deal. At the same time, the FTC approved Pfizer USD 43bn acquisition of Seagen (reverse breakup fee of USD 2.2bn - 5.19% of the deal value). Natixis Corporate & Investment Banking #healthcaresector #m&a #biotech #antitrust #bigpharma

The wide scope of #mergercontrol in the UK (and elsewhere) is illustrated by the review of the proposed acquisition by Theramex HQ UK Limited of the European rights to Viatris Inc’s Femoston and Duphaston products. This appears to concern (as the "target") only "certain rights, assets and title to commercialise certain pharmaceutical products in the UK [and certain other European countries]". Merger control needs to be thought about in a surprisingly wide range of mergers/acquisitions/JVs worldwide. https://lnkd.in/erKTjdV6

Another successful transaction facilitated by Benchmark International! Learn more about how we helped Medius AG and Regenold GmbH reach a successful agreement. https://lnkd.in/ezZsu4-S #MergersAndAcquisitions #BenchmarkInternational #SellSide #StrategicSeller #DealCompletion #MakeADeal #Success #Mergers #Acquisitions #BenchmarkSuccess #Business

:: Blackstone nears deal to sell S.Korean pharma wholesaler to MBK Partners, sources say :: Private equity firm Blackstone Inc (BX.N) is nearing a deal to sell its controlling stake in South Korean wholesale drug distributor Geo-Young to North Asian buyout fund MBK Partners for over $1 billion, three sources said. Blackstone is in final negotiations with Seoul-headquartered MBK about the sale and signing of the deal could happen soon, said one of the sources, who all declined to be named as the information is confidential. https://lnkd.in/dpge7629 #compaxed #ib #privateequity #deals #pe #investmnets #manda #ma #mergersandacquisitions #buyabusiness #transaction

FTC lays out roadmap for merger review in overhaul of decade-old antitrust framework >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #pharma #healthcare #biotech